Analysts See $-0.08 EPS for MicroVision, Inc. (MVIS); Athersys (ATHX) Sellers Decreased By 3.35% Their Shorts

Athersys, Inc. (NASDAQ:ATHX) Logo

Athersys Inc (NASDAQ:ATHX) had a decrease of 3.35% in short interest. ATHX’s SI was 10.60 million shares in July as released by FINRA. Its down 3.35% from 10.97M shares previously. With 374,400 avg volume, 28 days are for Athersys Inc (NASDAQ:ATHX)’s short sellers to cover ATHX’s short positions. The stock decreased 4.70% or $0.07 during the last trading session, reaching $1.42. About 988,303 shares traded or 29.82% up from the average. Athersys, Inc. (NASDAQ:ATHX) has declined 14.93% since July 22, 2018 and is downtrending. It has underperformed by 19.36% the S&P500. Some Historical ATHX News: 13/03/2018 - ATHERSYS & HEALIOS REPORT LOI TO EXPAND MULTISTEM® PACT; 13/03/2018 - Athersys: Healios Making $21M Equity Investment at $1.76/Shr; 13/03/2018 - ATHERSYS WOULD GET COMMITTED PAYMENTS OF $35M; 13/03/2018 - ATHERSYS INC ATHX.O - WILL PAY AN ADDITIONAL $25 MLN IN LICENSE/OPTION FEES, IN INSTALLMENTS; 23/03/2018 - HEALIOS K.K. REPORTS 8.7 PCT STAKE IN ATHERSYS INC AS OF MARCH 13, 2018 - SEC FILING; 22/04/2018 - DJ Athersys Inc, Inst Holders, 1Q 2018 (ATHX); 23/04/2018 - UTHEALTH, ATHERSYS TO CONDUCT MULTISTEM CELL THERAPY TRIAL; 01/05/2018 - ATHERSYS, HEALIOS EXTENSION TO COMPLETE EXPANSION TERMS; 13/03/2018 - ATHERSYS INC ATHX.O - WOULD RECEIVE COMMITTED PAYMENTS OF $35 MLN, AS WELL AS ADDITIONAL PAYMENTS, INCLUDING MILESTONES AND ROYALTIES; 13/03/2018 - ATHERSYS INC ATHX.O - CO, HEALIOS K.K. ANNOUNCED INTENT TO SIGNIFICANTLY EXPAND THEIR EXISTING DEVELOPMENT AND COMMERCIALIZATION COLLABORATION

Analysts expect MicroVision, Inc. (NASDAQ:MVIS) to report $-0.08 EPS on July, 30.They anticipate $0.02 EPS change or 20.00% from last quarter’s $-0.1 EPS. After having $-0.08 EPS previously, MicroVision, Inc.’s analysts see 0.00% EPS growth. The stock decreased 13.28% or $0.1142 during the last trading session, reaching $0.7459. About 2.19M shares traded or 380.22% up from the average. MicroVision, Inc. (NASDAQ:MVIS) has declined 43.53% since July 22, 2018 and is downtrending. It has underperformed by 47.96% the S&P500. Some Historical MVIS News: 09/05/2018 - MicroVision 1Q Loss/Shr 9c; 09/05/2018 - MICROVISION - AGREEMENT GRANTS A EXCLUSIVE, FIVE-YEAR LICENSE TO DISPLAY-ONLY TECHNOLOGY; 26/04/2018 - MicroVision Ships Samples of Next Generation of High-Resolution MEMS Scanner; 09/05/2018 - MicroVision, Inc. Announces New License Agreement With a Leading Technology Co; 11/05/2018 - Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marin; 19/04/2018 - DJ MicroVision Inc, Inst Holders, 1Q 2018 (MVIS); 03/05/2018 - MicroVision Delivers LiDAR Sensing Samples with New Time-of-Flight ASICS; 09/05/2018 - MicroVision 1Q Loss $7.13M; 09/05/2018 - MICROVISION - ENTERED INTO LICENSE AGREEMENT TO ALLOW LICENSEE TO USE CO’S DISPLAY TECHNOLOGY TO MANUFACTURE & SELL DISPLAY-ONLY ENGINES; 09/05/2018 - MicroVision, Inc. Announces New License Agreement with a Leading Technology Company

More notable recent MicroVision, Inc. (NASDAQ:MVIS) news were published by: Nasdaq.com which released: “MicroVision (MVIS) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq” on July 18, 2019, also Globenewswire.com with their article: “MicroVision Announces Second Quarter 2019 Results Nasdaq:MVIS - GlobeNewswire” published on July 18, 2019, Nasdaq.com published: “9 Augmented Reality Stocks to Buy - Nasdaq” on June 28, 2019. More interesting news about MicroVision, Inc. (NASDAQ:MVIS) were released by: Benzinga.com and their article: “Mid-Morning Market Update: Markets Open Higher; American Express Profit Tops Expectations - Benzinga” published on July 19, 2019 as well as Benzinga.com‘s news article titled: “Mid-Day Market Update: Microvision Falls On Downbeat Q2 Results; Midatech Pharma Shares Jump - Benzinga” with publication date: July 19, 2019.

MicroVision, Inc. develops PicoP scanning technology that provides high-resolution miniature projection, and three-dimensional sensing and image capture solutions in the United States. The company has market cap of $77.22 million. The Company’s PicoP scanning technology comprises a small form factor and lower power scanning engine for display, 3D sensing, and user interaction applications. It currently has negative earnings. The firm licenses its products primarily to original design manufacturers and original equipment manufacturers.

Investors sentiment increased to 1.27 in Q1 2019. Its up 0.33, from 0.94 in 2018Q4. It is positive, as 3 investors sold MicroVision, Inc. shares while 8 reduced holdings. 7 funds opened positions while 7 raised stakes. 22.72 million shares or 0.76% more from 22.55 million shares in 2018Q4 were reported. Northern Tru Corp invested in 176,216 shares or 0% of the stock. Royal Bancshares Of Canada reported 2,907 shares stake. Tradewinds Capital Management Ltd Liability Corp invested in 0.01% or 14,063 shares. Northwestern Mutual Wealth Mgmt Co accumulated 300 shares. Reilly Fin Advsrs Llc invested 0% of its portfolio in MicroVision, Inc. (NASDAQ:MVIS). Wells Fargo & Com Mn owns 133,649 shares. Geode Cap Mgmt Limited reported 0% in MicroVision, Inc. (NASDAQ:MVIS). Moreover, Charles Schwab Mngmt has 0% invested in MicroVision, Inc. (NASDAQ:MVIS). Hilton Cap Lc invested in 25,000 shares. Bankshares Of America De has invested 0% in MicroVision, Inc. (NASDAQ:MVIS). Bankshares Of New York Mellon Corporation has 40,101 shares for 0% of their portfolio. 1.13 million were reported by Perkins Cap Management Inc. Jpmorgan Chase And Co has invested 0% in MicroVision, Inc. (NASDAQ:MVIS). Susquehanna Gru Llp stated it has 0% in MicroVision, Inc. (NASDAQ:MVIS). Regions Financial Corp invested in 500 shares.

Investors sentiment increased to 1.13 in 2019 Q1. Its up 0.13, from 1 in 2018Q4. It improved, as 12 investors sold Athersys, Inc. shares while 18 reduced holdings. 8 funds opened positions while 26 raised stakes. 28.76 million shares or 0.27% more from 28.68 million shares in 2018Q4 were reported. California Employees Retirement System has 0% invested in Athersys, Inc. (NASDAQ:ATHX). Wealthtrust Fairport Limited Liability Co holds 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX) for 19,252 shares. Royal Bancshares Of Canada owns 7,800 shares or 0% of their US portfolio. Jpmorgan Chase And holds 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX) for 46,215 shares. Geode Cap Management Ltd Liability Corp reported 1.43 million shares stake. Livingston Grp Asset Mngmt (Operating As Southport Cap Management) has 30,000 shares. 6.12M are owned by Vanguard Group Inc. Montag A And Assoc Incorporated holds 0% in Athersys, Inc. (NASDAQ:ATHX) or 10,000 shares. 50,000 were reported by Pnc Fincl Serv Group. Ancora Advisors Llc invested 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX). Massachusetts-based State Street Corp has invested 0% in Athersys, Inc. (NASDAQ:ATHX). Illinois-based Northern Trust Corporation has invested 0% in Athersys, Inc. (NASDAQ:ATHX). Raymond James & Associate has invested 0% in Athersys, Inc. (NASDAQ:ATHX). Tower Research Limited Liability Corporation (Trc) invested in 4,777 shares. Legal And General Grp Public Limited Liability reported 19,051 shares stake.

More notable recent Athersys, Inc. (NASDAQ:ATHX) news were published by: Nasdaq.com which released: “Athersys (ATHX) Upgraded to Strong Buy: Here’s What You Should Know - Nasdaq” on April 23, 2019, also Finance.Yahoo.com with their article: “Volatility 101: Should Athersys (NASDAQ:ATHX) Shares Have Dropped 25%? - Yahoo Finance” published on May 24, 2019, Nasdaq.com published: “What Makes Athersys (ATHX) a New Buy Stock - Nasdaq” on March 19, 2019. More interesting news about Athersys, Inc. (NASDAQ:ATHX) were released by: Globenewswire.com and their article: “Athersys Reports First Quarter 2019 Results Nasdaq:ATHX - GlobeNewswire” published on May 08, 2019 as well as Globenewswire.com‘s news article titled: “Athersys to Participate in Two Upcoming Healthcare Conferences - GlobeNewswire” with publication date: April 01, 2019.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company has market cap of $212.68 million. The Company’s clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. It currently has negative earnings. The companyÂ’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers.

MicroVision, Inc. (NASDAQ:MVIS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.